Taofeek K. Owonikoko Named Candidate for ASCO President-Elect

Taofeek K. Owonikoko Named Candidate for ASCO President-Elect

Taofeek K. Owonikoko, MD, PhD, FASCO, Executive Director of the Marlene and Stewart Greenebaum Comprehensive Cancer Center at the University of Maryland, Baltimore, has been announced as a candidate for the position of President-Elect of the American Society of Clinical Oncology (ASCO).

The position carries a four-year term and represents one of the Society’s most significant leadership responsibilities.

With extensive experience in academic oncology, cancer center administration, and ASCO governance, Dr. Owonikoko brings a background that combines clinical leadership, institutional management, and longstanding service to the oncology community.

A Career Dedicated to Cancer Leadership

Dr. Owonikoko currently holds several senior leadership positions at the University of Maryland.

In addition to serving as Executive Director of the Marlene and Stewart Greenebaum Comprehensive Cancer Center, he is the Senior Associate Dean of Cancer Programs at the University of Maryland School of Medicine and Associate Vice President of Cancer Programs at the University of Maryland, Baltimore.

These appointments place him at the intersection of cancer research, academic medicine, and institutional leadership, with responsibilities spanning multiple aspects of oncology programs.

His professional career has also included substantial involvement in ASCO, where he has contributed to organizational governance, educational programming, and strategic initiatives.

From the ASCO Board to the President-Elect Candidacy

Dr. Owonikoko served on the ASCO Board of Directors from 2021 to 2025, including a term as Society Treasurer from 2024 to 2025.

During his Board tenure, he participated in several committees responsible for key aspects of the Society’s operations, including the Audit, Finance, and Compensation Committees.

His involvement extended beyond financial and administrative oversight. He also contributed to several ASCO Board task forces addressing issues relevant to oncology professionals and the broader cancer care community.

Most recently, he served on the ASCO Board Task Force on ABIM Maintenance of Certification (MOC) and Recertification, as well as the ASCO Board Task Force on Engaging Patient Advocates.

These roles reflect his involvement in discussions surrounding professional certification, physician development, and patient participation in oncology initiatives.

A Longstanding Commitment to Oncology Education

Education has been another important component of Dr. Owonikoko’s service to ASCO.

In 2021, he chaired the ASCO Annual Meeting Education Program Committee, contributing to the development of educational programming for one of the world’s largest gatherings of oncology professionals.

He previously served as a member of the Annual Meeting Scientific Program Committee, participating in the Society’s scientific meeting activities.

His leadership development within ASCO dates back to 2015, when he graduated from the Society’s Leadership Development Program.

Together, these appointments demonstrate more than a decade of involvement in ASCO’s educational, scientific, and leadership activities.

The Next Chapter in ASCO Leadership

The President-Elect position is an important part of ASCO’s leadership succession process, with a four-year term encompassing responsibilities across the Society’s presidential leadership cycle.

Dr. Owonikoko’s candidacy follows years of service within the organization, including his work on the Board of Directors, his tenure as Treasurer, and his participation in committees and task forces addressing professional and organizational priorities.

His experience in both academic cancer center leadership and ASCO governance provides a foundation for his candidacy as the Society prepares for its next leadership cycle.

The election outcome will determine who assumes the President-Elect position.

Editorial note: The information provided identifies Dr. Owonikoko as a candidate for the President-Elect seat, not as the confirmed winner. The headline and article therefore use “candidate” rather than stating that he has been elected.

More articles like this are available on OncoDaily.

Vahe Grigoryan
Fact checked by Vahe Grigoryan MD, Editorial Director
Vahe Grigoryan
Medically reviewed by Vahe Grigoryan MD, Editorial Director